Pfizer Faces Transition Challenges and Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Source: NASDAQ.COM
- Revenue Decline Risk: Pfizer's revenue peaked at $100 billion in 2022, but the decline in demand for COVID-related products and the expiration of patents for key blockbusters have led to a significant risk of revenue and stock price decline, necessitating a portfolio renewal to drive future growth.
- Key Trials Launch: In its latest earnings report, Pfizer indicated that this year will see the initiation of 20 significant pivotal trials, particularly in the promising obesity drug market, which is expected to reach nearly $100 billion by the end of the decade, with Pfizer entering this high-demand sector through the acquisition of Metsera.
- Pipeline Dependency: Pfizer's future growth heavily relies on the success of its development pipeline, especially for its obesity drug candidate; failure of key candidates in clinical trials could significantly impact the company's stock performance and overall market position.
- Market Competition Pressure: While Pfizer has potential advantages in the obesity drug sector, it faces intense competition from established players like Eli Lilly and Novo Nordisk, and must demonstrate the efficacy and market appeal of its new products in a crowded marketplace.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.100
Low
24.00
Averages
28.56
High
35.00
Current: 27.100
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Faces Revenue Decline Challenges
- Significant Revenue Decline: Pfizer's revenue plummeted from over $101 billion in 2022 to less than $63 billion last year, reflecting a drastic shrinkage due to the temporary boost from COVID vaccines and pills, which has raised concerns about its growth prospects in the market.
- Acquisition Strategy Enhances Pipeline: In 2023, Pfizer acquired oncology company Seagen for $43 billion, aiming to transform cancer treatment options through its antibody-drug conjugates, while also acquiring GLP-1 drugmaker Metsera for up to $10 billion last year to capitalize on opportunities in the anti-obesity drug market.
- Drug Development Potential: With over 100 drug candidates in its pipeline, Pfizer faces near-term risks from patent cliffs on key drugs, but these assets could help restore growth and boost investor confidence in the long run.
- Attractive Valuation: Trading at less than 10 times its estimated future earnings, Pfizer's stock, despite recent rallies, remains at 2013 levels, indicating substantial upside potential, and investors who overlook it today may regret their decision in the future.
See More
Pfizer's Future Growth Potential Analysis
- Revenue Decline Context: Pfizer's revenue plummeted from over $101 billion in 2022 to less than $63 billion in 2023, reflecting the waning benefits from its COVID vaccine and pill, yet the company is actively expanding its product pipeline.
- Acquisition Strategy: Pfizer acquired oncology company Seagen for $43 billion, aiming to transform cancer treatment with its antibody-drug conjugates, and last year it also acquired GLP-1 drugmaker Metsera for up to $10 billion, indicating its strategic positioning in the anti-obesity drug market.
- Rich R&D Pipeline: With over 100 drug candidates in development, Pfizer faces risks from patent expirations but has a robust pipeline that could significantly enhance its growth prospects, potentially shifting investor perceptions.
- Valuation Appeal: Trading at less than 10 times its estimated future earnings, Pfizer's stock remains undervalued despite recent rallies, still hovering around 2013 levels, suggesting substantial upside potential, and investors who overlook this opportunity may regret it in the future.
See More
Major Leadership Change Expected at PhRMA
- Leadership Change: Stephen Ubl, the long-time president and CEO of PhRMA, is expected to resign months before his contract ends, which may impact the organization's strategic direction and industry influence.
- Tenure Context: Ubl has led PhRMA since September 2025 after over a decade at AdvaMed, and his resignation may be linked to recent drug pricing deals made by the Trump administration, reflecting shifts in both internal and external pressures within the industry.
- Political Implications: His departure comes just ahead of the U.S. midterm elections, which could significantly affect PhRMA's influence on drug policy and industry positions, especially as drug pricing issues gain prominence during the election cycle.
- Industry Reaction: PhRMA has not yet responded to Ubl's resignation, and the industry's reaction remains unclear, but it may spark widespread discussion on how new leadership will address current drug policy challenges.
See More
New Rules for CDC Immunization Committee Selection Released
- New Regulation Implementation: The Department of Health and Human Services has released new rules for selecting members of the CDC's Advisory Committee on Immunization Practices (ACIP), replacing the invalidated appointments by a federal court to ensure transparency and fairness in the selection process.
- Court Ruling Impact: A Boston-based U.S. District Court has stayed the appointments of 13 ACIP members, emphasizing the need for rigorous screening in member selection, which may affect future vaccine policy formulation.
- Expanded Expertise Requirements: The renewed ACIP charter broadens the expertise required for individuals wishing to serve on the committee, aiming to incorporate specialists from various fields to enhance the committee's decision-making capabilities.
- Vaccine Coverage Implications: The recommendations made by ACIP are crucial for vaccine manufacturers, as their decisions directly influence the types and doses of vaccines Americans should receive, thereby impacting health insurance coverage.
See More
U.S. Economic Outlook Dims Amid Iran Tensions
- Market Weakness: The S&P 500 index showed significant weakness as President Trump's deadline for Iran approached, with most of the session in the red, reflecting investor concerns over economic prospects amid declining consumer confidence and rising inflation.
- Retail Sector Decline: Walmart's 3.3% drop indicates that even budget-conscious consumers may cut back on spending during an economic downturn, suggesting a deteriorating overall consumer health that could have long-term implications for the retail sector.
- Cruise Industry Struggles: Shares of Royal Caribbean, Norwegian Cruise Line, and Carnival fell nearly 3%, 3.3%, and 2.96% respectively, indicating a potential decline in consumer demand for travel post-pandemic, which raises further concerns about economic recovery.
- Pharmaceutical Stocks Underperform: Merck, Pfizer, and AbbVie saw declines of 1.3%, 2.6%, and 0.2%, respectively, highlighting inflationary pressures and the dual challenges of economic slowdown and rising costs faced by the pharmaceutical industry.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
Pfizer Faces Revenue Decline Challenges
- Significant Revenue Decline: Pfizer's revenue plummeted from over $101 billion in 2022 to less than $63 billion last year, reflecting a drastic shrinkage due to the temporary boost from COVID vaccines and pills, which has raised concerns about its growth prospects in the market.
- Acquisition Strategy Enhances Pipeline: In 2023, Pfizer acquired oncology company Seagen for $43 billion, aiming to transform cancer treatment options through its antibody-drug conjugates, while also acquiring GLP-1 drugmaker Metsera for up to $10 billion last year to capitalize on opportunities in the anti-obesity drug market.
- Drug Development Potential: With over 100 drug candidates in its pipeline, Pfizer faces near-term risks from patent cliffs on key drugs, but these assets could help restore growth and boost investor confidence in the long run.
- Attractive Valuation: Trading at less than 10 times its estimated future earnings, Pfizer's stock, despite recent rallies, remains at 2013 levels, indicating substantial upside potential, and investors who overlook it today may regret their decision in the future.
See More
Pfizer's Future Growth Potential Analysis
- Revenue Decline Context: Pfizer's revenue plummeted from over $101 billion in 2022 to less than $63 billion in 2023, reflecting the waning benefits from its COVID vaccine and pill, yet the company is actively expanding its product pipeline.
- Acquisition Strategy: Pfizer acquired oncology company Seagen for $43 billion, aiming to transform cancer treatment with its antibody-drug conjugates, and last year it also acquired GLP-1 drugmaker Metsera for up to $10 billion, indicating its strategic positioning in the anti-obesity drug market.
- Rich R&D Pipeline: With over 100 drug candidates in development, Pfizer faces risks from patent expirations but has a robust pipeline that could significantly enhance its growth prospects, potentially shifting investor perceptions.
- Valuation Appeal: Trading at less than 10 times its estimated future earnings, Pfizer's stock remains undervalued despite recent rallies, still hovering around 2013 levels, suggesting substantial upside potential, and investors who overlook this opportunity may regret it in the future.
See More
Major Leadership Change Expected at PhRMA
- Leadership Change: Stephen Ubl, the long-time president and CEO of PhRMA, is expected to resign months before his contract ends, which may impact the organization's strategic direction and industry influence.
- Tenure Context: Ubl has led PhRMA since September 2025 after over a decade at AdvaMed, and his resignation may be linked to recent drug pricing deals made by the Trump administration, reflecting shifts in both internal and external pressures within the industry.
- Political Implications: His departure comes just ahead of the U.S. midterm elections, which could significantly affect PhRMA's influence on drug policy and industry positions, especially as drug pricing issues gain prominence during the election cycle.
- Industry Reaction: PhRMA has not yet responded to Ubl's resignation, and the industry's reaction remains unclear, but it may spark widespread discussion on how new leadership will address current drug policy challenges.
See More
New Rules for CDC Immunization Committee Selection Released
- New Regulation Implementation: The Department of Health and Human Services has released new rules for selecting members of the CDC's Advisory Committee on Immunization Practices (ACIP), replacing the invalidated appointments by a federal court to ensure transparency and fairness in the selection process.
- Court Ruling Impact: A Boston-based U.S. District Court has stayed the appointments of 13 ACIP members, emphasizing the need for rigorous screening in member selection, which may affect future vaccine policy formulation.
- Expanded Expertise Requirements: The renewed ACIP charter broadens the expertise required for individuals wishing to serve on the committee, aiming to incorporate specialists from various fields to enhance the committee's decision-making capabilities.
- Vaccine Coverage Implications: The recommendations made by ACIP are crucial for vaccine manufacturers, as their decisions directly influence the types and doses of vaccines Americans should receive, thereby impacting health insurance coverage.
See More
U.S. Economic Outlook Dims Amid Iran Tensions
- Market Weakness: The S&P 500 index showed significant weakness as President Trump's deadline for Iran approached, with most of the session in the red, reflecting investor concerns over economic prospects amid declining consumer confidence and rising inflation.
- Retail Sector Decline: Walmart's 3.3% drop indicates that even budget-conscious consumers may cut back on spending during an economic downturn, suggesting a deteriorating overall consumer health that could have long-term implications for the retail sector.
- Cruise Industry Struggles: Shares of Royal Caribbean, Norwegian Cruise Line, and Carnival fell nearly 3%, 3.3%, and 2.96% respectively, indicating a potential decline in consumer demand for travel post-pandemic, which raises further concerns about economic recovery.
- Pharmaceutical Stocks Underperform: Merck, Pfizer, and AbbVie saw declines of 1.3%, 2.6%, and 0.2%, respectively, highlighting inflationary pressures and the dual challenges of economic slowdown and rising costs faced by the pharmaceutical industry.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
